Latest Insider Transactions at Incyte Corp (INCY)
This section provides a real-time view of insider transactions for Incyte Corp (INCY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INCYTE CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INCYTE CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2024
|
Susanne Schaffert Director |
SELL
Payment of exercise price or tax liability
|
Direct |
752
-20.65%
|
$44,368
$59.94 P/Share
|
|
Jun 12
2024
|
Otis W Brawley Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+24.47%
|
-
|
|
Jun 12
2024
|
Katherine A High Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+20.73%
|
-
|
|
Jun 12
2024
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+14.41%
|
-
|
|
Jun 12
2024
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+13.38%
|
-
|
|
Jun 12
2024
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
19,164
-22.4%
|
$1,149,840
$60.0 P/Share
|
|
Jun 12
2024
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+13.2%
|
-
|
|
Jun 12
2024
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+15.07%
|
-
|
|
Jun 06
2024
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,093
-4.81%
|
$63,394
$58.91 P/Share
|
|
May 07
2024
|
Baker Bros. Advisors LP |
BUY
Exercise of conversion of derivative security
|
Indirect |
30,000
+0.27%
|
$1,470,000
$49.01 P/Share
|
|
Mar 28
2024
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
413
+3.05%
|
$23,128
$56.97 P/Share
|
|
Mar 28
2024
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
403
+2.49%
|
$22,568
$56.97 P/Share
|
|
Mar 28
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
1,086
+0.01%
|
-
|
|
Mar 25
2024
|
Matteo Trotta EVP, GM, Dermatology US |
BUY
Grant, award, or other acquisition
|
Direct |
7,828
+50.0%
|
-
|
|
Feb 14
2024
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,377
+7.03%
|
-
|
|
Feb 14
2024
|
Paula J Swain EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
7,377
+7.99%
|
-
|
|
Feb 14
2024
|
Herve Hoppenot Chairman / CEO |
BUY
Grant, award, or other acquisition
|
Direct |
41,577
+7.64%
|
-
|
|
Feb 14
2024
|
Barry P Flannelly EVP & General Manager US |
BUY
Grant, award, or other acquisition
|
Direct |
7,377
+7.98%
|
-
|
|
Feb 14
2024
|
Vijay K Iyengar EVP, GMAPPS |
BUY
Grant, award, or other acquisition
|
Direct |
7,377
+12.68%
|
-
|
|
Feb 14
2024
|
Christiana Stamoulis EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,377
+7.58%
|
-
|
|
Feb 12
2024
|
Christiana Stamoulis EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
387
-0.47%
|
$22,059
$57.84 P/Share
|
|
Jan 22
2024
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-0.24%
|
$6,588
$61.5 P/Share
|
|
Jan 22
2024
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-0.15%
|
$6,588
$61.5 P/Share
|
|
Jan 19
2024
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
122
-0.27%
|
$7,442
$61.49 P/Share
|
|
Jan 19
2024
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
122
-0.17%
|
$7,442
$61.49 P/Share
|
|
Jan 18
2024
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
BUY
Grant, award, or other acquisition
|
Direct |
8,114
+15.39%
|
$494,954
$61.18 P/Share
|
|
Jan 18
2024
|
Michael James Morrissey EVP, Head of Tech. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
11,359
+13.54%
|
$692,899
$61.18 P/Share
|
|
Jan 17
2024
|
Thomas Tray Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,021
-4.36%
|
$62,281
$61.48 P/Share
|
|
Jan 17
2024
|
Barry P Flannelly EVP & General Manager US |
SELL
Payment of exercise price or tax liability
|
Direct |
3,675
-4.52%
|
$224,175
$61.48 P/Share
|
|
Jan 17
2024
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
101
-0.28%
|
$6,161
$61.48 P/Share
|
|
Jan 17
2024
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
101
-0.16%
|
$6,161
$61.48 P/Share
|
|
Jan 16
2024
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
101
-0.28%
|
$6,161
$61.34 P/Share
|
|
Jan 16
2024
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
101
-0.16%
|
$6,161
$61.34 P/Share
|
|
Jan 03
2024
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,365
-7.55%
|
$478,725
$65.51 P/Share
|
|
Jan 02
2024
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Open market or private sale
|
Direct |
657
-1.49%
|
$42,705
$65.0 P/Share
|
|
Dec 29
2023
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
1,112
+0.01%
|
-
|
|
Dec 29
2023
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
423
+3.22%
|
$26,226
$62.79 P/Share
|
|
Dec 29
2023
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
412
+2.61%
|
$25,544
$62.79 P/Share
|
|
Dec 13
2023
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,067
-4.35%
|
$66,154
$62.37 P/Share
|
|
Dec 12
2023
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
210
-0.85%
|
$11,970
$57.36 P/Share
|
|
Oct 02
2023
|
Sheila A. Denton EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
26,524
+50.0%
|
-
|
|
Sep 29
2023
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
1,020
+0.01%
|
-
|
|
Sep 29
2023
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
389
+3.07%
|
$22,173
$57.77 P/Share
|
|
Sep 29
2023
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
379
+2.47%
|
$21,603
$57.77 P/Share
|
|
Sep 01
2023
|
Paula J Swain EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
8,449
-9.83%
|
$549,185
$65.13 P/Share
|
|
Aug 01
2023
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,511
-18.06%
|
$1,355,193
$63.28 P/Share
|
|
Jul 14
2023
|
Barry P Flannelly EVP & General Manager US |
BUY
Grant, award, or other acquisition
|
Direct |
9,668
+10.62%
|
-
|
|
Jul 14
2023
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,535
+10.21%
|
-
|
|
Jul 14
2023
|
Herve Hoppenot Chairman / CEO |
BUY
Grant, award, or other acquisition
|
Direct |
43,184
+9.03%
|
-
|
|
Jul 14
2023
|
Pablo J Cagnoni President, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
9,668
+4.57%
|
-
|